Physician profile
Joris Schuller
NPI 1790743128
$3,624.39
in general payments reported to CMS, 2019-2025
30 companies · $696 in 2025
The $696 reported for 2025 was more than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $399 · 2020: $191 · 2021: $315 · 2022: $454 · 2023: $765 · 2024: $804 · 2025: $696.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,263 · Education: $2.05.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,262.97 |
| Education | $2.05 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $1,058.96 | 2019-2025 | Farxiga, Lokelma |
| Veloxis Pharmaceuticals, INC. | $564.63 | 2019-2025 | Envarsus |
| Vifor Pharma, INC. | $300.38 | 2019-2023 | Veltassa |
| Alexion Pharmaceuticals, INC. | $209.13 | 2019-2025 | Ultomiris |
| Amgen INC. | $185.28 | 2023-2025 | Krystexxa, Tavneos |
| Fresenius USA Marketing, INC. | $181.81 | 2021-2024 | Velphoro, Korsuva |
| Cormedix INC. | $128.44 | 2024 | Defencath |
| Nxstage Medical, INC. | $127.69 | 2019-2025 | Nxstage System One, Nxstage Cartridge Express, Nxstage Pureflow Solution |
| Opko Pharmaceuticals, LLC | $114.46 | 2019-2024 | Rayaldee |
| La Jolla Pharmaceutical Company | $59.17 | 2019-2020 | |
| Glaxosmithkline, LLC. | $56.60 | 2023-2024 | Benlysta |
| Horizon Therapeutics Plc | $54.47 | 2023 | Krystexxa |
| Mallinckrodt Enterprises LLC | $48.76 | 2019 | |
| Otsuka America Pharmaceutical, INC. | $47.22 | 2025 | Jynarque |
| Novo Nordisk INC | $46.31 | 2022-2024 | Ozempic |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Aurinia Pharma U.S., INC. | $45.47 | 2024-2025 | Lupkynis |
| Novartis Pharmaceuticals Corporation | $44.97 | 2024-2025 | |
| Janssen Pharmaceuticals, INC | $44.71 | 2019-2020 | |
| Calliditas Therapeutics US INC. | $33.69 | 2025 | Tarpeyo |
| Apellis Pharmaceuticals, INC. | $32.84 | 2025 | Empaveli |
| Genentech USA, INC. | $31.24 | 2019 | |
| Shionogi INC | $29.38 | 2025 | Fetroja |
| Merck Sharp & Dohme LLC | $28.66 | 2025 | Zerbaxa |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $28.56 | 2025 | |
| Alafair Biosciences, INC. | $25.39 | 2024 | Versawrap |
| Recor Medical INC | $25.26 | 2024 | Paradise Renal Denervation System |
| Travere Therapeutics, INC. | $24.16 | 2022-2025 | Filspari |
| Bayer Healthcare Pharmaceuticals INC. | $16.23 | 2023 | |
| Scpharmaceuticals INC. | $16.09 | 2025 | |
| Ultragenyx Pharmaceutical INC. | $14.43 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Joris Schuller listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.